文献速递关节外科

低分子肝素与手术部位出血并发症的相对风险:全关节置换术后静脉血栓预防随机对照试验的系统综述与Meta分析结果

Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
PubMed 文献 · J Arthroplasty · 2017-04-14

该系统综述与Meta分析纳入45项随机对照试验共56,730例全髋或全膝关节置换术后患者,比较低分子肝素与其他血栓预防药物的手术部位出血风险。结果显示,与对照组相比低分子肝素显著增加手术部位出血风险(RR 2.32,95%CI 1.40-3.85),与华法林相比亦显著增加(RR 1.54,95%CI 1.23-1.94),与阿哌沙班相比风险有升高趋势(RR 1.27,95%CI 1.00-1.63),与利伐沙班相似(RR 0.95,95%CI 0.74-1.23)。

要点

  • 低分子肝素较对照组显著增加手术部位出血风险(RR 2.32,95%CI 1.40-3.85)。
  • 低分子肝素较华法林显著增加手术部位出血风险(RR 1.54,95%CI 1.23-1.94)。
  • 低分子肝素与利伐沙班出血风险相似(RR 0.95,95%CI 0.74-1.23)。

核心结论

  • 与对照组和华法林相比,低分子肝素增加手术部位出血风险;与达比加群相比亦增加风险;与阿哌沙班相比有风险升高趋势;与利伐沙班相比出血风险相似。

研究设计与样本

  • 系统综述与Meta分析,遵循PRISMA指南,纳入比较低分子肝素、华法林、利伐沙班、阿哌沙班、达比加群、阿司匹林或不进行药物预防中至少两种的全髋或全膝关节置换术后患者的随机对照试验。
  • 共纳入45项随机对照试验,56,730例患者,进行5项Meta分析分别比较低分子肝素与对照、华法林、阿哌沙班、利伐沙班和达比加群。

主要发现

  • 低分子肝素与对照组相比手术部位出血相对风险显著增加(RR 2.32,95%CI 1.40-3.85)。
  • 低分子肝素与华法林相比手术部位出血相对风险显著增加(RR 1.54,95%CI 1.23-1.94)。
  • 低分子肝素与阿哌沙班相比手术部位出血相对风险呈升高趋势(RR 1.27,95%CI 1.00-1.63)。
  • 低分子肝素与利伐沙班相比手术部位出血相对风险相似(RR 0.95,95%CI 0.74-1.23)。
  • 仅1项研究报告低分子肝素与达比加群相比手术部位出血风险(RR 5.97,95%CI 2.08-17.11)。

局限性

  • 仅1项研究报告低分子肝素与达比加群的手术部位出血风险(RR 5.97,95%CI 2.08-17.11)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism causes significant morbidity and mortality in patients after total joint arthroplasty. Although network meta-analyses have demonstrated a benefit of various thromboprophylactic agents, there remains a concern in the surgical community regarding the resulting wound complications. There is currently no systematic review of the surgical site bleeding complications of thromboprophylactic agents. The aim of this study was to systematically review the surgical site bleeding outcomes of venous thromboembolism prophylaxis in this population. METHODS: A systematic review and meta-analysis was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Randomized controlled trials comparing more than one of low-molecular-weight heparin (LMWH), warfarin, rivaroxaban, apixaban, dabigatran, aspirin, or no pharmacologic treatment in patients after total hip or knee arthroplasty were selected for inclusion. Five meta-analyses were performed to compare LMWH with control, warfarin, apixaban, rivaroxaban, and dabigatran. RESULTS: Forty-five randomized controlled trials of 56,730 patients were included. LMWH had a significantly increased relative risk of surgical site bleeding in comparison with control (relative risk, 2.32; 95% confidence interval, 1.40-3.85) and warfarin (1.54; 1.23-1.94). The relative risk of LMWH trended higher than apixaban (1.27; 1.00-1.63) and was similar to rivaroxaban (0.95; 0.74-1.23). Only 1 study reported the risk of surgical site bleeding in LMWH vs dabigatran (5.97; 2.08-17.11). CONCLUSION: LMWH increased the risk of surgical site bleeding compared with control, warfarin. and dabigatran and trended toward an increased risk compared with apixaban. The risk of surgical site bleeding was similar with LMWH and rivaroxaban.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Suen K, Westh RN, Churilov L, et al. Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty. J Arthroplasty. 2017. PMID: 28522244. doi:10.1016/j.arth.2017.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。